BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic‐related mutations in BRCA1 associated with an increased risk of ovarian cancer |
| |
| Authors: | Tingyan Shi Pan Wang Caixia Xie Sheng Yin Di Shi Congchong Wei Wenbin Tang Rong Jiang Xi Cheng Qingyi Wei Qing Wang Rongyu Zang |
| |
| Affiliation: | 1. Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Gynecology & Obstetrics, Zhongshan hospital, Fudan University, Shanghai, China;2. Shanghai Topgen Bio‐Pharm Co, Ltd, Shanghai, China;3. Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;4. Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China;5. Duke Cancer Institute, Duke University Medical Center, Durham, NC;6. Plateforme de génomique des cancers, Centre Léon Bérard, Laboratoire de la génétique constitutionnelle HCL‐CLB, Lyon, France |
| |
| Abstract: | BRCA1/2 are cancer predisposition genes involved in hereditary breast and ovarian cancer (HBOC). Mutation carriers display an increased sensitivity to inhibitors of poly(ADP‐ribose) polymerase (PARP). Despite a number of small‐size hospital‐based studies being previously reported, there is not yet, to our knowledge, precise data of BRCA1/2 mutations among Chinese ovarian cancer patients. We performed a multicenter cohort study including 916 unselected consecutive epithelial ovarian cancer (EOC) patients from eastern China to screen for BRCA1/2 mutations using the next‐generation sequencing approach. A total of 153 EOC patients were found to carry pathogenic germline mutations in BRCA1/2, accounting for an overall mutation incidence of 16.7% with the predominance in BRCA1 (13.1%) compared with BRCA2 (3.9%). We identified 53 novel pathogenic mutations, among which the c.283_286delCTTG and the c.4573C > T of BRCA1 were both found in two unrelated patients. More importantly, the most common mutation found in this study, c.5470_5477del8 was most likely to be Chinese population‐related without an apparent founder origin. This hot‐spot mutation was presumably associated with an increased risk of ovarian cancer. Taken together, germline BRCA1/2 mutations were common in Chinese EOC patients with distinct mutational spectrum compared to Western populations. Our study contributes to the current understanding of BRCA1/2 mutation prevalence worldwide. We recommend BRCA1/2 genetic testing to all Chinese women diagnosed with EOC to identify HBOC families, to provide genetic counseling and clinical management for at‐risk relatives. Mutation carriers may also benefit from PARP‐targeted therapies. |
| |
| Keywords: | ovarian cancer BRCA1 gene BRCA2 gene mutation |
|
|
